KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Research & Development (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Research & Development for 13 consecutive years, with $87.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 47.46% to $87.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $300.9 million, a 43.04% increase, with the full-year FY2025 number at $300.9 million, up 43.04% from a year prior.
  • Research & Development was $87.7 million for Q4 2025 at Xenon Pharmaceuticals, up from $77.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $87.7 million in Q4 2025 to a low of $16.3 million in Q1 2021.
  • A 5-year average of $43.0 million and a median of $42.0 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 104.11% in 2023, then increased 11.98% in 2024.
  • Xenon Pharmaceuticals' Research & Development stood at $21.9 million in 2021, then surged by 59.14% to $34.8 million in 2022, then rose by 17.93% to $41.1 million in 2023, then surged by 44.79% to $59.5 million in 2024, then soared by 47.46% to $87.7 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Research & Development are $87.7 million (Q4 2025), $77.1 million (Q3 2025), and $75.0 million (Q2 2025).